Metropolis Healthcare Limited (MHL) announced the approval of key agreements for its subsidiary, Metropolis Quality Solutions Private Limited (MQSPL). This restructuring involves a ₹1.1 crore investment by Medsource Ozone Biomedicals Private Limited (Medsource) and an additional ₹16 lakh by Dr. Puneet Kumar Nigam. The transaction will lead to a revised shareholding in MQSPL, with MHL’s stake becoming 54.90% on a fully diluted basis.
Strategic Restructuring of Subsidiary Approved
Metropolis Healthcare Limited (MHL) has announced a significant strategic move involving its subsidiary, Metropolis Quality Solutions Private Limited (MQSPL). The Board of Directors has approved the execution of a Share Subscription Agreement and a Shareholder’s Agreement, marking a pivotal step in consolidating and streamlining MQSPL’s External Quality Assessment Services Business.
Key Investment and Stakeholder Agreements
The approved agreements include the Share Subscription Agreement with Medsource Ozone Biomedicals Private Limited (“Medsource”) and Dr. Puneet Kumar Nigam, alongside a Shareholder’s Agreement involving Medsource, MHL, and Dr. Puneet Kumar Nigam. This initiative aims to integrate operational leadership, clinical and diagnostic backing, research and development, and product development capabilities to foster business scale.
Financial Commitments and Shareholding Changes
Under the terms of the agreements, Medsource and Dr. Puneet Kumar Nigam will collectively invest approximately INR 1.10 crore and INR 16 lakh, respectively, into MQSPL. Following the completion of these transactions and the conversion of optionally convertible redeemable preference shares issued to Dr. Puneet Kumar Nigam over a five-year period, the shareholding structure of MQSPL will be adjusted. On a fully diluted basis, MHL will hold 54.90%, Medsource will hold 30.60%, and Dr. Puneet Kumar Nigam will hold 14.50%.
Governance and Operational Impact
The Shareholder’s Agreement will grant MHL and Medsource the right to nominate Directors to the Board of MQSPL, subject to the SHA’s terms. This restructuring is intended to consolidate the External Quality Assessment Services Business under MQSPL, bringing together essential operational and development capabilities to facilitate business expansion. There will be no change in the shareholding pattern of Metropolis Healthcare Limited itself as a result of this transaction.
Source: BSE
